Development of replication-deficient adenovirus malaria vaccines
Introduction: Malaria remains a major threat to endemic populations and travelers, including military personnel to these areas. A malaria vaccine is feasible, as radiation attenuated sporozoites induce nearly 100% efficacy. Areas covered: This review covers current malaria clinical trials using aden...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-03-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2016.1228454 |
| _version_ | 1827813262958264320 |
|---|---|
| author | Michael R. Hollingdale Martha Sedegah Keith Limbach |
| author_facet | Michael R. Hollingdale Martha Sedegah Keith Limbach |
| author_sort | Michael R. Hollingdale |
| collection | DOAJ |
| description | Introduction: Malaria remains a major threat to endemic populations and travelers, including military personnel to these areas. A malaria vaccine is feasible, as radiation attenuated sporozoites induce nearly 100% efficacy. Areas covered: This review covers current malaria clinical trials using adenoviruses and pre-clinical research. Heterologous prime-boost regimens, including replication-deficient human adenovirus 5 (HuAd5) carrying malaria antigens, are efficacious. However, efficacy appears to be adversely affected by pre-existing anti-HuAd5 antibodies. Current strategies focus on replacing HuAd5 with rarer human adenoviruses or adenoviruses isolated from non-human primates (NHPs). The chimpanzee adenovirus ChAd63 is undergoing evaluation in clinical trials including infants in malaria-endemic areas. Key antigens have been identified and are being used alone, in combination, or with protein subunit vaccines. Gorilla adenoviruses carrying malaria antigens are also currently being evaluated in preclinical models. These replacement adenovirus vectors will be successfully used to develop vaccines against malaria, as well as other infectious diseases. Expert commentary: Simplified prime-boost single shot regimens, dry-coated live vector vaccines or silicon microneedle arrays could be developed for malaria or other vaccines. Replacement vectors with similar or superior immunogenicity have rapidly advanced, and several are now in extensive Phase 2 and beyond in malaria as well as other diseases, notably Ebola. |
| first_indexed | 2024-03-11T23:30:08Z |
| format | Article |
| id | doaj.art-ba19c3f503524a11bc3ac47289c88eee |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T23:30:08Z |
| publishDate | 2017-03-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-ba19c3f503524a11bc3ac47289c88eee2023-09-20T10:18:01ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952017-03-0116326127110.1080/14760584.2016.12284541228454Development of replication-deficient adenovirus malaria vaccinesMichael R. Hollingdale0Martha Sedegah1Keith Limbach2Naval Medical Research CenterNaval Medical Research CenterNaval Medical Research CenterIntroduction: Malaria remains a major threat to endemic populations and travelers, including military personnel to these areas. A malaria vaccine is feasible, as radiation attenuated sporozoites induce nearly 100% efficacy. Areas covered: This review covers current malaria clinical trials using adenoviruses and pre-clinical research. Heterologous prime-boost regimens, including replication-deficient human adenovirus 5 (HuAd5) carrying malaria antigens, are efficacious. However, efficacy appears to be adversely affected by pre-existing anti-HuAd5 antibodies. Current strategies focus on replacing HuAd5 with rarer human adenoviruses or adenoviruses isolated from non-human primates (NHPs). The chimpanzee adenovirus ChAd63 is undergoing evaluation in clinical trials including infants in malaria-endemic areas. Key antigens have been identified and are being used alone, in combination, or with protein subunit vaccines. Gorilla adenoviruses carrying malaria antigens are also currently being evaluated in preclinical models. These replacement adenovirus vectors will be successfully used to develop vaccines against malaria, as well as other infectious diseases. Expert commentary: Simplified prime-boost single shot regimens, dry-coated live vector vaccines or silicon microneedle arrays could be developed for malaria or other vaccines. Replacement vectors with similar or superior immunogenicity have rapidly advanced, and several are now in extensive Phase 2 and beyond in malaria as well as other diseases, notably Ebola.http://dx.doi.org/10.1080/14760584.2016.1228454malariavaccineadenovirusreplication-deficienthuman adenovirus 5chimpanzee adenovirus 63gorilla adenoviruscd8+ t cellsantibodiesefficacy |
| spellingShingle | Michael R. Hollingdale Martha Sedegah Keith Limbach Development of replication-deficient adenovirus malaria vaccines Expert Review of Vaccines malaria vaccine adenovirus replication-deficient human adenovirus 5 chimpanzee adenovirus 63 gorilla adenovirus cd8+ t cells antibodies efficacy |
| title | Development of replication-deficient adenovirus malaria vaccines |
| title_full | Development of replication-deficient adenovirus malaria vaccines |
| title_fullStr | Development of replication-deficient adenovirus malaria vaccines |
| title_full_unstemmed | Development of replication-deficient adenovirus malaria vaccines |
| title_short | Development of replication-deficient adenovirus malaria vaccines |
| title_sort | development of replication deficient adenovirus malaria vaccines |
| topic | malaria vaccine adenovirus replication-deficient human adenovirus 5 chimpanzee adenovirus 63 gorilla adenovirus cd8+ t cells antibodies efficacy |
| url | http://dx.doi.org/10.1080/14760584.2016.1228454 |
| work_keys_str_mv | AT michaelrhollingdale developmentofreplicationdeficientadenovirusmalariavaccines AT marthasedegah developmentofreplicationdeficientadenovirusmalariavaccines AT keithlimbach developmentofreplicationdeficientadenovirusmalariavaccines |